US › Healthcare

Scynexis Inc (SCYX)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$4.45+8.27%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$235,000

Revenue YoY

-82.8%

Net profit

$7.4M

EPS

$-0.32

EPS estimate

$-0.40

Net margin

3,147.7%

EPS came in at -0.32 against a street estimate of -0.40 — a beat of 20.0%.

Key statistics

Market cap

$43.7M

Forward P/E

1.9

P/B

0.68

Book value

$6.73

EPS (TTM)

$-0.87

52-week high

$9.20

52-week low

$3.53

50-day MA

$4.79

200-day MA

$5.69

Beta

1.11

Analyst view

Analysts rate Scynexis Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $36.55.

Shareholding

Insiders

1.99%

Institutions

61.95%

Largest institutional holders

Fund	Stake
Great Point Partners LLC	9.49%
Squadron Capital Management LLC	7.61%
Propel Bio Management LLC	5.46%
Adage Capital Partners Gp LLC	5.46%
Heights Capital Management Inc	2.62%
Avidity Partners Management LP	2.62%
Kingdon Capital Management LLC	2.49%
Vanguard Capital Management, LLC	1.97%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Scynexis Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.